Grufman P, Wolpert E Z, Sandberg J K, Kärre K
Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden.
Eur J Immunol. 1999 Jul;29(7):2197-204. doi: 10.1002/(SICI)1521-4141(199907)29:07<2197::AID-IMMU2197>3.0.CO;2-B.
We recently demonstrated that spleen cells primed against dominant BALB.B antigens can inhibit the cytotoxic T lymphocyte (CTL) response against subdominant antigens in vitro. In this study, we show that this interference is dependent on CD8+, but not CD4+, T cells directed against dominant antigens. Similar to immunodominance in vivo, T cell interference in vitro required presentation of dominant and subdominant antigens by the same antigen-presenting cell. In vivo priming with cells expressing dominant and subdominant antigens did not induce long-lasting unresponsiveness against the latter. These results support a model in which immunodominance is mediated by T cell competition. In line with this, we found that the immunodominance effects in the CTL response against these minor histocompatibility antigens could be broken by immunization with live bone marrow-derived dendritic cells.
我们最近证明，针对显性BALB.B抗原致敏的脾细胞在体外可抑制针对隐性抗原的细胞毒性T淋巴细胞（CTL）反应。在本研究中，我们表明这种干扰依赖于针对显性抗原的CD8+而非CD4+ T细胞。与体内免疫显性类似，体外T细胞干扰要求同一抗原呈递细胞呈递显性和隐性抗原。用表达显性和隐性抗原的细胞进行体内致敏不会诱导对后者的持久无反应性。这些结果支持一种模型，即免疫显性由T细胞竞争介导。与此一致，我们发现针对这些次要组织相容性抗原的CTL反应中的免疫显性效应可通过用活的骨髓来源的树突状细胞免疫来打破。
